Gene expression analysis of peripheral T-cell lymphoma not otherwise specified reveals two distinct subgroups and recurrent pdgfrα deregulation
S.A. Pileri, P.P. Piccaluga, C. Agostinelli, S. Zupo, A. Carbone, F. Facchetti, B. Falini
M. Ferrarini, A. Gallamini, D. Novero, M. Paulli, P.L. Zinzani, R. Dalla Favera
Institute of Haematology and Medical Oncology L. and A. Seràgnoli, Haematology and
Haematopathology Units, University of Bologna, Italy; Institute for Cancer
Genetics, Columbia University, New York; Division of Medical Oncology C,
National Cancer Research Institute, Genoa University, Italy; National Institute for Cancer, Milan, Italy; Department of Pathology, Brescia University, Italy; Institute of Haematology, Perugia University, Italy; Haematology Unit, S. Croce and Carle Hospital, Cuneo, Italy; Department of Biomedical Science and Human Oncology – Pathologic Anatomy Section, Turin University, Italy; Department of Human and Genetic Pathology – Pathologic Anatomy Section, Pavia University, Italy
Peripheral T-cell lymphomas (PTCLs) represent approximately 12% of lymphoid neoplasms.1 Their incidence varies in different countries and races, being higher in HTLV-1 endemic areas (Asia, Caribbean basin and some parts of the United States).2 PTCLs are a heterogeneous group of tumours that in the REAL/WHO Classification are roughly subdivided into specified and unspecified (or not otherwise specified, NOS) forms.
[>Read full article in PDF]